TB-500
Also known as Thymosin Beta-4 fragment
Actin-binding peptide fragment
A synthetic fragment of thymosin beta-4 studied for cell migration, flexibility and systemic tissue repair.
How it works
TB-500 is a synthetic fragment of thymosin beta-4, a naturally occurring protein involved in cell structure and repair. Its core mechanism involves binding G-actin, a building block of the cell's internal skeleton, which promotes remodeling of the cytoskeleton and supports cell movement toward areas of injury.
This actin-binding activity is proposed to drive endothelial cell migration and new blood vessel formation, mechanisms that overlap with but are distinct from the VEGF pathway emphasized in BPC-157 research. The result, in animal models, is faster recruitment of repair cells to injured tissue.
Cardiac and dermal research models report improved post-ischemic tissue recovery and faster wound closure, alongside reduced markers of local inflammation. Because TB-500 acts on a fundamental cytoskeletal pathway rather than a single tissue type, its research applications span cardiac, dermal, and musculoskeletal models.
What research has shown
Animal models report improved cardiac tissue recovery post-ischemia, faster dermal wound closure and reduced inflammatory markers.
Reported ranges in the literature
Low end
2 mg weekly
Optimal
2 to 5 mg weekly during a 4 to 6 week loading phase
High end
5 to 10 mg weekly split across 2 administrations
Frequency reported in the literature: 1 to 2× weekly; loading phase then maintenance. Note: Frequently paired with BPC-157 in published repair research models.
Frequently asked questions
What is TB-500?
TB-500 is a synthetic fragment of thymosin beta-4 studied for its role in cell migration, flexibility, and systemic tissue repair signaling.
How does TB-500 differ from BPC-157?
TB-500 works through actin-binding and cell migration pathways, while BPC-157 emphasizes VEGF-driven angiogenesis. Both are studied for tissue repair and are frequently combined in research protocols.
What does the research show?
Animal studies report improved cardiac tissue recovery following induced ischemia, faster dermal wound closure, and reduced local inflammatory markers.
How is TB-500 typically studied in dosing schedules?
Published research designs often use a loading phase of higher frequency dosing for several weeks, followed by a lower maintenance frequency.
How long are research blocks typically?
Reported protocols commonly run 4 to 6 weeks for the loading phase, sometimes followed by an extended maintenance phase depending on the tissue model studied.
Related compounds
Further reading
Research use only
All content on this page is general reference information for laboratory research contexts. It is not medical advice, is not intended to direct human use, and does not replace guidance from a licensed healthcare professional. Not for human consumption. Must be 18+.